Symbols / LSTA Stock $3.08 -6.10% Lisata Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
LSTA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Ho…
Exch · Country NCM · United States
Market Cap 28.05M
Enterprise Value 14.73M
Income -16.35M
Sales 170.00K
FCF (ttm) -8.06M
Book/sh 1.68
Cash/sh 1.43
Employees 21
Insider 10d —
IPO Mar 01, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.67
PEG 118.40
P/S 164.99
P/B 1.83
P/C —
EV/EBITDA -0.86
EV/Sales 86.67
Quick Ratio 3.94
Current Ratio 4.23
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.86
EPS next Y -0.66
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2025-11-06
ROA -50.26%
ROE -91.41%
ROIC —
Gross Margin 100.00%
Oper. Margin -101.79%
Profit Margin 0.00%
Shs Outstand 9.11M
Shs Float 7.19M
Insider Own 20.89%
Instit Own 7.96%
Short Float 0.93%
Short Ratio 0.76
Short Interest 70.25K
52W High 5.07
vs 52W High -39.25%
52W Low 1.81
vs 52W Low 70.17%
Beta —
Impl. Vol. —
Rel Volume 0.57
Avg Volume 73.88K
Volume 42.21K
Target (mean) $9.50
Tgt Median $9.50
Tgt Low $4.00
Tgt High $15.00
# Analysts 2
Recom None
Prev Close $3.28
Price $3.08
Change -6.10%
About

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.50
Mean price target
2. Current target
$3.08
Latest analyst target
3. DCF / Fair value
$-15.93
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.08
Low
$4.00
High
$15.00
Mean
$9.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-21 down Brookline Capital Buy → Hold —
2025-08-21 reit HC Wainwright & Co. Buy → Buy $15
2025-07-15 main Brookline Capital Buy → Buy $32
2024-12-11 reit HC Wainwright & Co. Buy → Buy $15
2024-11-21 reit HC Wainwright & Co. Buy → Buy $15
2024-09-18 reit HC Wainwright & Co. Buy → Buy $15
2024-08-13 reit HC Wainwright & Co. Buy → Buy $15
2024-07-19 reit HC Wainwright & Co. Buy → Buy $15
2024-07-10 reit HC Wainwright & Co. Buy → Buy $15
2024-06-14 reit HC Wainwright & Co. Buy → Buy $15
2024-05-21 reit HC Wainwright & Co. Buy → Buy $15
2024-04-26 reit HC Wainwright & Co. Buy → Buy $15
2024-04-25 reit HC Wainwright & Co. Buy → Buy $15
2024-03-01 reit HC Wainwright & Co. Buy → Buy $15
2024-01-04 reit HC Wainwright & Co. Buy → Buy $15
2023-08-15 reit HC Wainwright & Co. Buy → Buy $15
2023-05-25 reit HC Wainwright & Co. Buy → Buy $15
2023-03-31 reit HC Wainwright & Co. — → Buy $15
2022-10-19 main HC Wainwright & Co. — → Buy $15
News
RSS: Latest LSTA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-09 BROWN GREGORY B Director — 30,456 $0.00 $0
2026-01-09 MAZZO DAVID J Officer and Director — 81,000 $0.00 $0
2026-01-09 KLOSK STEVEN MARK Director — 30,456 $0.00 $0
2026-01-09 AZAB MOHAMMAD Director — 30,456 $0.00 $0
2026-01-09 HENSON HEIDI Director — 30,456 $0.00 $0
2026-01-09 FLOWERS CYNTHIA LOUISE Director — 30,456 $0.00 $0
2026-01-09 BUCK KRISTEN K Officer — 25,000 $0.00 $0
2026-01-09 NISCO JAMES Officer — 15,000 $0.00 $0
2026-01-09 IMAM TARIQ General Counsel — 15,000 $0.00 $0
2025-01-08 BROWN GREGORY B Director — 15,789 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.17
-83.00%
1.00
0.00
0.00
Operating Revenue
0.17
-83.00%
1.00
0.00
0.00
Operating Expense
18.38
-21.49%
23.41
-8.94%
25.71
-55.37%
57.60
Research And Development
7.95
-29.87%
11.33
-10.99%
12.73
-70.70%
43.46
Selling General And Administration
10.43
-13.62%
12.07
-6.93%
12.97
-8.25%
14.14
General And Administrative Expense
10.43
-13.62%
12.07
-6.93%
12.97
-8.25%
14.14
Other Gand A
10.43
-13.62%
12.07
-6.93%
12.97
-8.25%
14.14
Total Expenses
18.38
-21.49%
23.41
-8.94%
25.71
-55.37%
57.60
Operating Income
-18.21
+18.74%
-22.41
+12.83%
-25.71
+55.37%
-57.60
Total Operating Income As Reported
-18.21
+18.74%
-22.41
+12.83%
-25.71
+55.37%
-57.60
EBITDA
-18.06
+18.76%
-22.23
+12.87%
-25.52
+55.64%
-57.53
Normalized EBITDA
-18.87
+21.76%
-24.12
+14.61%
-28.24
+51.79%
-58.58
Reconciled Depreciation
0.15
-16.09%
0.17
-7.94%
0.19
+173.91%
0.07
EBIT
-18.21
+18.74%
-22.41
+12.83%
-25.71
+55.37%
-57.60
Total Unusual Items
0.81
-57.20%
1.88
-30.87%
2.72
+158.94%
1.05
Total Unusual Items Excluding Goodwill
0.81
-57.20%
1.88
-30.87%
2.72
+158.94%
1.05
Net Income
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Pretax Income
-17.55
+15.57%
-20.78
+10.30%
-23.17
+59.14%
-56.70
Other Income Expense
0.66
-59.35%
1.63
-35.93%
2.54
+182.94%
0.90
Other Non Operating Income Expenses
-0.14
+43.58%
-0.26
-38.17%
-0.19
-20.00%
-0.15
Gain On Sale Of Security
0.81
-57.20%
1.88
-30.87%
2.72
+158.94%
1.05
Tax Provision
-0.96
-20.55%
-0.80
+65.75%
-2.33
+6.01%
-2.48
Tax Rate For Calcs
0.00
+42.77%
0.00
-61.82%
0.00
+130.02%
0.00
Tax Effect Of Unusual Items
0.04
-38.89%
0.07
-73.61%
0.27
+495.61%
0.05
Net Income Including Noncontrolling Interests
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Net Income From Continuing Operation Net Minority Interest
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Net Income From Continuing And Discontinued Operation
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Net Income Continuous Operations
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Minority Interests
0.00
0.00
0.00
0.00
Normalized Income
-17.35
+20.41%
-21.80
+6.42%
-23.29
+57.83%
-55.23
Net Income Common Stockholders
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Diluted EPS
-1.91
+20.42%
-2.40
+6.98%
-2.58
+75.36%
-10.47
Basic EPS
-1.91
+20.42%
-2.40
+6.98%
-2.58
+75.36%
-10.47
Basic Average Shares
8.69
+4.30%
8.33
+3.17%
8.07
+55.85%
5.18
Diluted Average Shares
8.69
+4.30%
8.33
+3.17%
8.07
+55.85%
5.18
Diluted NI Availto Com Stockholders
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
17.74
-49.31%
35.00
-36.00%
54.69
-25.11%
73.03
Current Assets
17.70
-48.80%
34.58
-35.88%
53.92
-24.98%
71.88
Cash Cash Equivalents And Short Term Investments
15.96
-48.93%
31.25
-38.17%
50.53
-27.00%
69.23
Cash And Cash Equivalents
15.96
-1.56%
16.21
-28.26%
22.59
-29.74%
32.15
Cash Equivalents
—
—
16.71
-39.59%
27.67
Cash Financial
—
—
5.88
+31.03%
4.49
Other Short Term Investments
0.00
-100.00%
15.04
-46.19%
27.94
-24.63%
37.07
Receivables
0.00
-100.00%
0.90
0.00
—
Accounts Receivable
0.00
-100.00%
0.90
0.00
—
Prepaid Assets
—
—
—
—
Other Current Assets
1.75
-28.20%
2.43
-28.21%
3.39
+27.89%
2.65
Total Non Current Assets
0.04
-90.33%
0.42
-44.94%
0.77
-33.51%
1.16
Net PPE
0.02
-75.00%
0.07
-58.86%
0.17
-40.88%
0.30
Gross PPE
0.49
-25.26%
0.66
+0.00%
0.66
-7.29%
0.71
Accumulated Depreciation
-0.48
+19.19%
-0.59
-21.19%
-0.49
-16.55%
-0.42
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.49
-16.13%
0.59
+0.00%
0.59
-4.07%
0.61
Leases
0.00
-100.00%
0.07
+0.00%
0.07
-27.27%
0.10
Goodwill And Other Intangible Assets
0.00
-100.00%
0.19
-27.00%
0.26
-21.26%
0.33
Other Intangible Assets
—
0.19
-27.00%
0.26
-21.26%
0.33
Other Non Current Assets
0.02
-85.63%
0.16
-51.81%
0.33
-37.12%
0.53
Total Liabilities Net Minority Interest
3.14
-44.71%
5.68
-16.40%
6.80
+1.34%
6.71
Current Liabilities
3.07
-45.29%
5.61
-14.83%
6.59
+3.24%
6.38
Payables And Accrued Expenses
3.07
-43.92%
5.48
-14.73%
6.42
+3.53%
6.20
Payables
1.02
-20.64%
1.28
-46.96%
2.42
-8.81%
2.65
Accounts Payable
1.02
-20.64%
1.28
-46.96%
2.42
-8.81%
2.65
Current Accrued Expenses
2.05
-51.05%
4.19
+4.77%
4.00
+12.77%
3.55
Current Debt And Capital Lease Obligation
—
0.14
-18.45%
0.17
-6.67%
0.18
Current Capital Lease Obligation
0.00
-100.00%
0.14
-18.45%
0.17
-6.67%
0.18
Total Non Current Liabilities Net Minority Interest
0.07
+0.00%
0.07
-65.71%
0.21
-35.78%
0.33
Long Term Debt And Capital Lease Obligation
—
—
—
0.30
Long Term Capital Lease Obligation
—
—
—
0.30
Other Non Current Liabilities
0.07
+0.00%
0.07
-65.71%
0.21
-35.78%
0.33
Stockholders Equity
14.86
-49.76%
29.57
-38.58%
48.15
-27.68%
66.58
Common Stock Equity
14.86
-49.76%
29.57
-38.58%
48.15
-27.68%
66.58
Capital Stock
0.01
+12.50%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+12.50%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
—
—
—
0.00
Share Issued
8.83
+5.05%
8.41
+3.18%
8.15
+3.16%
7.90
Ordinary Shares Number
8.83
+5.05%
8.41
+3.18%
8.15
+3.16%
7.90
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
580.24
+0.32%
578.42
+0.25%
576.97
+0.42%
574.55
Retained Earnings
-564.65
-3.03%
-548.07
-3.78%
-528.08
-4.11%
-507.24
Gains Losses Not Affecting Retained Earnings
-0.04
+54.32%
-0.08
-92.86%
-0.04
-44.83%
-0.03
Treasury Stock
0.71
+0.00%
0.71
+0.00%
0.71
+0.00%
0.71
Minority Interest
-0.25
+0.00%
-0.25
+0.00%
-0.25
+0.00%
-0.25
Other Equity Adjustments
-0.04
+54.32%
-0.08
-92.86%
-0.04
-44.83%
-0.03
Total Equity Gross Minority Interest
14.60
-50.20%
29.32
-38.79%
47.89
-27.79%
66.32
Total Capitalization
14.86
-49.76%
29.57
-38.58%
48.15
-27.68%
66.58
Working Capital
14.63
-49.48%
28.96
-38.81%
47.33
-27.73%
65.49
Invested Capital
14.86
-49.76%
29.57
-38.58%
48.15
-27.68%
66.58
Total Debt
0.00
-100.00%
0.14
-18.45%
0.17
-6.67%
0.18
Capital Lease Obligations
0.00
-100.00%
0.14
-18.45%
0.17
-6.67%
0.18
Net Tangible Assets
14.86
-49.44%
29.38
-38.65%
47.88
-27.71%
66.24
Tangible Book Value
14.86
-49.44%
29.38
-38.65%
47.88
-27.71%
66.24
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.95
+17.60%
-19.36
+3.37%
-20.03
+5.38%
-21.17
Cash Flow From Continuing Operating Activities
-15.95
+17.60%
-19.36
+3.37%
-20.03
+5.38%
-21.17
Net Income From Continuing Operations
-16.59
+17.01%
-19.98
+4.10%
-20.84
+61.57%
-54.23
Depreciation Amortization Depletion
0.15
-16.09%
0.17
-7.94%
0.19
+173.91%
0.07
Depreciation And Amortization
0.15
-16.09%
0.17
-7.94%
0.19
+173.91%
0.07
Other Non Cash Items
—
—
—
30.39
Stock Based Compensation
1.23
-25.83%
1.65
-18.89%
2.04
-22.69%
2.64
Provisionand Write Offof Assets
0.50
0.00
—
—
Asset Impairment Charge
0.13
0.00
—
—
Operating Gains Losses
—
0.13
+4233.33%
0.00
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.00
0.00
Change In Working Capital
-1.29
-47.42%
-0.87
-88.96%
-0.46
+44.40%
-0.83
Change In Receivables
0.40
+144.56%
-0.90
0.00
—
Changes In Account Receivables
0.40
+144.56%
-0.90
0.00
—
Change In Prepaid Assets
0.74
-12.91%
0.85
+203.40%
-0.82
+2.49%
-0.84
Change In Payables And Accrued Expense
-2.57
-158.29%
-0.99
-1230.68%
0.09
+139.46%
-0.22
Change In Payable
-2.57
-158.29%
-0.99
-1230.68%
0.09
—
Change In Account Payable
-2.57
-158.29%
-0.99
-1230.68%
0.09
—
Change In Other Current Assets
0.14
-17.65%
0.17
-37.96%
0.27
+15.61%
0.24
Investing Cash Flow
15.09
+14.00%
13.23
+30.99%
10.10
-65.06%
28.91
Cash Flow From Continuing Investing Activities
15.09
+14.00%
13.23
+30.99%
10.10
-65.06%
28.91
Net PPE Purchase And Sale
-0.03
0.00
0.00
+100.00%
-0.28
Purchase Of PPE
-0.03
0.00
0.00
+100.00%
-0.28
Capital Expenditure
-0.03
—
—
-0.28
Net Investment Purchase And Sale
15.11
+13.10%
13.36
+32.28%
10.10
-68.93%
32.52
Purchase Of Investment
-9.18
+83.52%
-55.69
+43.45%
-98.48
-9.80%
-89.69
Sale Of Investment
24.29
-64.82%
69.05
-36.41%
108.58
-11.15%
122.20
Net Business Purchase And Sale
0.00
+100.00%
-0.13
0.00
—
Purchase Of Business
0.00
+100.00%
-0.13
0.00
—
Net Other Investing Changes
—
—
—
-3.32
Financing Cash Flow
0.60
+390.78%
-0.21
-153.51%
0.39
+271.88%
-0.22
Cash Flow From Continuing Financing Activities
0.60
+390.78%
-0.21
-153.51%
0.39
+271.88%
-0.22
Net Common Stock Issuance
0.84
+1141.18%
0.07
-78.82%
0.32
+646.51%
0.04
Proceeds From Stock Option Exercised
0.01
0.00
-100.00%
0.15
0.00
Net Other Financing Charges
-0.25
+7.66%
-0.27
-201.10%
-0.09
+65.92%
-0.27
Changes In Cash
-0.26
+95.83%
-6.33
+33.69%
-9.54
-226.98%
7.52
Effect Of Exchange Rate Changes
0.01
+120.00%
-0.06
-243.75%
-0.02
-60.00%
-0.01
Beginning Cash Position
16.21
-28.26%
22.59
-29.74%
32.15
+30.46%
24.65
End Cash Position
15.96
-1.56%
16.21
-28.26%
22.59
-29.74%
32.15
Free Cash Flow
-15.98
+17.46%
-19.36
+3.37%
-20.03
+6.63%
-21.45
Interest Paid Supplemental Data
—
—
—
—
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
-0.07
+83.52%
-0.46
+52.60%
-0.96
-221.83%
0.79
Common Stock Issuance
0.84
+1141.18%
0.07
-78.82%
0.32
+646.51%
0.04
Earnings Losses From Equity Investments
0.00
-100.00%
0.13
0.00
—
Issuance Of Capital Stock
0.84
+1141.18%
0.07
-78.82%
0.32
+646.51%
0.04
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category